期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 20, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/ijms20051162
关键词
urothelial carcinoma; trichostatin A; histone deacetylase inhibitor; chemotherapy; paclitaxel
资金
- New Taipei City Hospital
- National Taiwan University Hospital [103-S2349, 104-M2868, 105-S2978, 105-28, 106-3415, 107-S3784]
- Taiwan Ministry and Science and Technology [107-2321-B-008-001, 107-2314-B-002-268-MY2]
- Taiwan Maple Urological Association
Trichostatin A (TSA), an antifungal antibiotic derived from Streptomyces, inhibits mammalian histone deacetylases, and especially, selectively inhibits class I and II histone deacetylase (HDAC) families of enzymes. TSA reportedly elicits an antiproliferative response in multifarious tumors. This study investigated the antitumor effects of TSA alone and in combination with paclitaxel when applied to two high-grade urothelial carcinoma (UC) cell lines (BFTC-905 and BFTC-909). Fluorescence-activated cell sorting, flow cytometry, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium assay were used to assess TSA's cytotoxicity and effects on apoptosis induction. TSA induced synergistic cytotoxicity, when combined with paclitaxel (combination index < 1), resulted in concomitant suppression of paclitaxel-induced activation of phospho-extracellular signal-regulated kinase (ERK) 1/2. A xenograft nude mouse model confirmed that TSA enhances the antitumor effects of paclitaxel. These findings demonstrate that the administration of TSA in combination with paclitaxel elicits a synergistic cytotoxic response. The results of this study indicate that the chemoresistance of UC could be circumvented by combining HDAC inhibitors to target the ERK pathway.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据